Mesoblast Ltd
Company Profile
Business description
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUST: +61 396396036
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
73
Mesoblast Ltd News & Analysis
stocks
Shorts circle BHP ahead of listing unification: ASX’s most shorted stocks
stocks
Mayne Pharma woes to persist for 2020
stocks
CSL remains favourite, but biotech field broadening
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,986.20 | 29.20 | -0.32% |
CAC 40 | 7,861.96 | 4.60 | 0.06% |
DAX 40 | 24,262.22 | 44.85 | 0.19% |
Dow JONES (US) | 44,461.28 | 171.71 | -0.38% |
FTSE 100 | 9,136.94 | 0.62 | 0.01% |
HKSE | 24,982.87 | 194.06 | -0.77% |
NASDAQ | 21,129.67 | 31.38 | 0.15% |
Nikkei 225 | 40,942.74 | 288.04 | 0.71% |
NZX 50 Index | 12,854.51 | 1.46 | -0.01% |
S&P 500 | 6,362.90 | 7.96 | -0.12% |
S&P/ASX 200 | 8,730.80 | 25.60 | -0.29% |
SSE Composite Index | 3,614.63 | 1.09 | -0.03% |